High-Dose Therapy in Acute Leukemia

References

• Cross M., Dexter T. M. Growth lactorh in development, transformation and tumorigenesis. Cell 1991; 64: 271–280
   PubMed Web of Science ®Google Scholar
• Fialkow P. J., Singer P. W., Raskind W. H., Adamson J. W., Jacobson R. J., Bemstein I. D., Dow L. W., Najfeld V., Veith R. Clonal development, stem-cell diflei-entiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 1987; 317: 468–477
   PubMed Web of Science ®Google Scholar
• Rabbitts T. H. Translocations, master genes, and differences between the origins of acute and chronic leukemias. Cell 1991; 61: 641–644
   Web of Science ®Google Scholar
• Stone R. M. Hematopoietic growth factors and leukemia. Curr Opin Oncol 1992; 4: 33–44
   PubMedGoogle Scholar
• Büchner T. Acute leukemia. Curr Opin Hematol 1993; 171–182
   Google Scholar
• Crump M., Keating A. Acute leukemia in adults. Curr Opin Hematol 1995; 2: 247–254
   PubMedGoogle Scholar
• Chopra R., Goldstone A. H. Modern trends in bone marrow transplantation for acuk myeloid and acute lymphoblastic leukemia. Curr Opin Oncol 1992; 4: 247–258
   PubMedGoogle Scholar
• Mayer R. J., Davis R. B., Schiffer C. A., Berg D. T., Powell B. L., Schulman P., Omura G. A., Moore J. O., McIntyre O. K., Frei E., III, lor the Cancer and Leukemia Group R. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Bloomfield C. D., Lawrence D., Arthur D. C., Berg D. T., Schiffer C. A., Mayer R. J. Curative impact of intensification with high-dose cytrabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood. 1994; 84(suppl 1)111a, (Abstract)
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Fisher L. D., Thomas E. D. Chemotherapy vs marrow transplantation lor adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 1988; 72: 179–184
   PubMed Web of Science ®Google Scholar
• Armitage J. O. Bone marrow transplantation. N Engl J Med 1994; 330: 827–838
   PubMed Web of Science ®Google Scholar
• Haynes A. P., Russell N. H. Blood stein cell allogralting. Curr Opin Hematol 1995; 2: 431–435
   PubMedGoogle Scholar
• Appelbaum F. R. Marrow trmsplantation for hematologic malignanices: a brief review of current status and future prospects. Semin Hematol 1988; 25(suppl 3)16–22
   PubMed Web of Science ®Google Scholar
• Advisory Committee of the International Autologous Bone Marrow Transplant Registry. Autologous Bone Marrow Transplant. Different indications in Europe and North America. Lancet 1989; 11: 317–318
   Google Scholar
• Zittoun R. A., Mandelli F., Willemze R., de Witte T., Labar B., Resegotti L., Leoni F., Damaaio E., Visani C., Papa G., Caronia F., Hayat M., Stryckmans P., Rotoli B., Leoni P., Peetermans M. E., Dardenne M., Vegna M. L., Petti M. C., Solbu G., Suciu S., for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute inyelogenous leukemia. N Engl J Med 1905; 332: 217–223
   Web of Science ®Google Scholar
• Burnett A. K., Goldstone A. H., Stevens R. F. The role of BMT in addition to intensive chemotherapy in AML in first CR: results of the MRC AML-10 trial. Blood. 1994; 84(suppl I)252a, (Abstract)
   Google Scholar
• Martens A. C. M., Van Bekkum D. W., Hagenbeek A. The BN acute myelocytic leukemia (BNML) (A rat model for studying human acute myelocytic leukemia (AML)). Leukenria 1990; 4: 241–257
   PubMed Web of Science ®Google Scholar
• Schultz F. W., Martens A. C. M., Hagenbeek A. The contribution of residual leukemic cells in the graft to leukemia relapse after autologous bone marrow transplantation: matherndtical considerations. Leukemia 1989; 3: 530–534
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Rill D. R., Holladay M. S., Heslop H. E., Moen R. C., Buschle M., Krance R. A., Santana V. M., Anderson F. W., Ihle J. N. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993; 342: 1134–1137
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Rill D. R., Moen R. C., Krance R. A., Mirro J., Jr., Anderson F. W., Ihle J. N. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Luncet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Gulati S. C., Acaba L. Rationale for purging in autologous stem cell transplantation. J Hematotherapy 1993; 2: 467–471
   PubMedGoogle Scholar
• Burnett A. K. Autologous transplantation in acute leukemias, including purging. Curr Opion Oncol 1990; 2: 263–268
   PubMedGoogle Scholar
• Berenson R. J., Andrews R. G., Bensinger W. I., Kalamasz D., Knitter G., Buckner C. D., Bernstein I. D. CD34+ marrow cells engraft lethally irradiated baboons. J Clir Invest 1988; 81: 951–954
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C., Cazzola M., De Fabritiis P., De Vincentiis A., Gianni A. M., Lanza F., Lauria F., Lemoli R. M., Tarella C., Zanon P., Tura S. CD34-positive cells: biology and clinical relevance. Haematologica 1995; 80: 367–387
   PubMedGoogle Scholar
• Berenson R. Transplantation of hematopoietic stem cells. J Hematotherapy 1993; 2: 347–349
   PubMedGoogle Scholar
• Santos G. W., Colvin M. O. Pharmacological purging of bone marrow with referene to autografting. Clinics Hematol 1986; 15: 67–83
   PubMedGoogle Scholar
• Uckun F. M., Gajl-Peczalska K., Meyers D. E., Ramsay N. C., Kersey J. H., Colvin M., Vallera D. A. Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. Blood 1987; 69: 361–366
   PubMed Web of Science ®Google Scholar
• Hervé P., Tamayo E., Peters A. Autologous stem cell grafting in acute myeloid leukemia: technical approach of marrow incubation in vitro with pharmacological agents (prerequisite for clinical applications). Br J Haematol 1983; 53: 683–684
   PubMed Web of Science ®Google Scholar
• Coulombel L., Kalousek D. K., Eaves C. J., Gupta C. M., Eaves A. C. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308: 1493–1498
   PubMed Web of Science ®Google Scholar
• Daley G. D., Goldman J. M. Autologous transplant for CML revisited. Exp Hematol 1993; 21: 734–737
   PubMed Web of Science ®Google Scholar
• Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M. A., Dick J. E. A cell initiating human acute myeloid leukaemia after transplantation intoSCID mice. Nature 1994; 367: 645–648
   PubMed Web of Science ®Google Scholar
• Santons G. W. The role of autologous hematopoietic stem cell transplantation in hematologic malignancy. Curr Opin Oncol 1994; 6: 115–121
   PubMedGoogle Scholar
• Sharkis S. J., Santos G. W., Colvin O. M. Elimination of acute myelogenous leukemic cells from marrow and tumor suspension in the rat with 4-hydroperoxycy-clophosphamide. Blood 1980; 55: 521–523
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans H. C., Martens A. C. M., Löwenberg B., Hagenbeek A. No preferential sensitivity of clonogenic AML cells to Asta-Z-7557. Leuk Res 1984; 8: 723–728
   PubMed Web of Science ®Google Scholar
• Rowley S. D., Colvin M., Stuart R. K. Human multilineage progenitor cell sensitivity to 4-hydroperoxycy-clophosphamide. Exp Hematol 1985; 13: 295–298
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C., Mangoni L., Almici C., Garau D., Craviotto L., Piovani G., Caramatti C., Rizroli V. Differential sensitivity of adherent CFU-Blast. CFU-Mix, BFU-E and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. Exp Hematol 1992; 20: 328–333
   PubMed Web of Science ®Google Scholar
• Douay L., Mary J. Y., Giarratana M. C., Najman A., Gorin N. C. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (Asta Z 7557). Exp Hematol 1989; 17: 429–432
   PubMed Web of Science ®Google Scholar
• Gorin N. C., Aegerter P., Auvert B., Meloni G., Goldstone A. H., Burnett A., Carella A., Korbling M., Hervé P., Maraninchi D., Löwenberg B., Verdonck L. F., de Planque M., Hermans J., Helbig W., Porcellini A., Rizzoli V., Alessandrino E. P., Franklin I. M., Reiffers J., Colleselli P., Goldman J. M. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606–1614
   PubMed Web of Science ®Google Scholar
• Rizzoli V., Mangoni L. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. Bone Marrow Purging and Processing, S. R. Gross, A. P. D. A. Gee. Alan Liss, New York 1990; 21–38, Worthington-White
   Google Scholar
• Carlo-Stella C., Mangoni L., Almici C., Cottafavi L., Meloni G., Mandelli F., Rizzoli V. Use of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. Blood 1992; 80: 2412–2418
   PubMed Web of Science ®Google Scholar
• Bullock G., Tang C., Tourkina E., Ibrado A. M., Lutzky J., Huang Y., Mahoney M. E., Bhalla K. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphaniide induced programmed cell death or apoptosis in human myeloid leukemia cells. Exp Hematol 1993; 21: 1640–1646
   PubMed Web of Science ®Google Scholar
• Skorski T., Kawalec M., Hoser G., Ratajczak M., Gnatowski B., Kawiak J. The kinetic of immunologic and hematologic recovery in mice after lethal total body irradiation and reconstitution with syngeneic bone marrow cells treated or untreated with mafosfamide (Asta Z 7654). Bone Marrow Transplant 1988; 3: 543–551
   PubMed Web of Science ®Google Scholar
• Almici C., Mangoni L., Carlo-Stella C., Garau D., Cottafavi L., Rizzoli V. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow. Bone Marrow Transplant 1995; 16: 95–101
   PubMed Web of Science ®Google Scholar
• Gorin N. C., Labopin M., Meloni G., Korbling M., Carella A., Herve P., Burnett A., Rizzoli V., Alessandrino E. P., Bjorkstrand B., Ferrant A., Lowenberg B., Coser P., Simonsson B., Helbig W., Brunet-Mauri S., Verdonck L. F., Iriondo A., Polii E., Colombat P., Franklin I. M., Souillet G., Willemze R. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 1991; 5: 896–904
   PubMed Web of Science ®Google Scholar
• Rizzoli V., Mangoni L., Carlo-Stella C. Autologous bone marrow transplantation in acute myelogenous leukemia. Leukemia 1992; 6: 1101–1106
   PubMed Web of Science ®Google Scholar